Abstract: A method for annotating dynamic content includes receiving a freeform annotation overlaid on dynamic content; determining whether the dynamic content changes; in response to a determination that the dynamic content changes, displaying an indicator corresponding to a region where the freeform annotation was created; determining whether the indicator is selected; in response to a determination that the indicator is selected, displaying a lightbox with the freeform annotation as it was overlaid on the dynamic content when it was created; determining whether the a revert button included in the lightbox is selected; and in response to a determination that the revert button is selected, displaying the freeform annotation overlaid on the dynamic content as it was created before the dynamic content changed.

Abstract: A method for annotating dynamic content includes receiving a freeform annotation overlaid on dynamic content; determining whether the dynamic content changes; in response to a determination that the dynamic content changes, displaying an indicator corresponding to a region where the freeform annotation was created; determining whether the indicator is selected; in response to a determination that the indicator is selected, displaying a lightbox with the freeform annotation as it was overlaid on the dynamic content when it was created; determining whether the a revert button included in the lightbox is selected; and in response to a determination that the revert button is selected, displaying the freeform annotation overlaid on the dynamic content as it was created before the dynamic content changed.

Abstract: The present invention relates to the use of avian cell lines for the preparation of seed influenza vaccines, and to vaccines made therefrom.

Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.